Baxter International Logo
US0718131099

Baxter International

Ins Portfolio

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +39,96(+27,87%). Der Median liegt bei +39,96(+27,87%).

Kaufen
  11
Halten
  14
Verkaufen
  1

Scoring-Modelle

Dividenden-Strategie3 / 15
HGI-Strategie3 / 18
Levermann-Strategie-2 / 13
Powered byaktien.guide

News

  • Foto von Baxter Stock Likely to Gain Following the Introduction of Voalte Linq

    Baxter Stock Likely to Gain Following the Introduction of Voalte Linq

    At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.» Mehr auf zacks.com

  • Foto von Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings

    Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings

    LAS VEGAS--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlined communication between care teams, with the goal of freeing up more of their time and energy to focus on.» Mehr auf businesswire.com

  • Foto von Medical Penlight Market Report 2025-2030, with BV Medical, Aspen Surgical Products, Baxter, Streamlight, GF Health Products, Rudolf Riester, American Diagnostic, HONSUN, Prestige Medical & more

    Medical Penlight Market Report 2025-2030, with BV Medical, Aspen Surgical Products, Baxter, Streamlight, GF Health Products, Rudolf Riester, American Diagnostic, HONSUN, Prestige Medical & more

    Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Medical Penlight Market Size, Share & Trends Analysis Report By Type (Consumables, Equipment), By Light Output (Oncology, Cardiovascular Diseases), By Usability (Disposable, Reusable), By End-use, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering. The global medical penlight market size was estimated at USD 279.7 million in 2024 and is projected to grow at a CAGR of 6.6% from 2024 to 2030. The market is driven significantly by the product's utility in diagnosing and assessing eye and ear conditions. According to a WHO report from August 2023, approximately 2.2 billion individuals experience distance vision impairment. Out of this group, vision impairment in at least 1 billion cases could have been prevented or remains untreated. Refractive errors and cataracts are identified as the primary causes of vision impairment and blindness worldwide. Medical professionals rely on penlights for their compact size, ease of use, and focused illumination, which are crucial in conducting detailed examinations of these sensitive areas. In ophthalmology, penlights are indispensable tools for examining the pupils, assessing pupil reactions to light, and detecting abnormalities such as irregularities in pupil size or shape, which can indicate neurological or ocular health issues. They are also crucial in assessing eye movements and conducting basic visual acuity tests, aiding in the diagnosis of conditions such as strabismus or nystagmus. The increasing prevalence of eye and ear disorders, coupled with advancements in penlight technology, is driving market growth. Manufacturers are innovating with features such as LED illumination for brighter and more efficient light output, ergonomic designs for comfortable handling during prolonged use, and enhanced durability for reliability in clinical environments. These advancements not only improve diagnostic accuracy but also streamline workflow efficiency in healthcare settings. In addition, otolaryngology (ENT), medical penlights are used for examining the ear canal, tympanic membrane, and assessing hearing conditions. They help ENT specialists to visualize abnormalities, foreign objects, and signs of infection or inflammation within the ear. Worldwide, the incidence of ENT conditions such as laryngitis, tonsillitis, sinusitis, and hearing loss is increasing. According to the World Health Organization (WHO), over 10% of the global population currently experiences varying degrees of hearing loss, a figure projected to approach nearly 2 billion by 2050. Penlights equipped with otoscopic attachments further enhance their utility by enabling magnified views and facilitating detailed inspections of the ear's internal structures. This capability is crucial for diagnosing conditions such as otitis media, ear wax buildup, and tympanic membrane perforations. Furthermore, the emphasis on preventive healthcare and early diagnosis is further boosting the demand in the medical penlights market. Routine screenings and examinations using penlights help in identifying eye and ear conditions at their early stages, enabling timely interventions and improving patient outcomes. As healthcare facilities continue to prioritize patient care and diagnostic accuracy, the role of medical penlights in supporting comprehensive eye and ear health assessments is expected to expand, driving continued market growth in the coming years. Global Medical Penlight Market Report Segmentation This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, the analyst has segmented the medical penlights market report on the basis of type, light output, usability, end use and region.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2025 hat Baxter International bereits +0,17 Dividende ausgeschüttet. Die letzte Dividende wurde im Januar gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Baxter International einen Umsatz von +2,65 Mrd und ein Nettoeinkommen von 492,04 Mio
(EUR)Dez. 2024
YOY
Umsatz+2,65 Mrd24,72%
Bruttoeinkommen+921,61 Mio30,79%
Nettoeinkommen492,04 Mio322,01%
EBITDA169,14 Mio123,58%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+15,48 Mrd
Anzahl Aktien
511,63 Mio
52 Wochen-Hoch/Tief
+40,41 - +26,03
Dividendenrendite
+3,10%
Dividenden TTM
+0,97
Nächste Dividende
+0,16
Beta
0,6
KGV (PE Ratio)
25,89
KGWV (PEG Ratio)
+0,04
KBV (PB Ratio)
+2,41
KUV (PS Ratio)
+1,31

Unternehmensprofil

Baxter International Inc. entwickelt und vertreibt über seine Tochtergesellschaften weltweit ein Portfolio von Gesundheitsprodukten. Das Unternehmen bietet Peritonealdialyse und Hämodialyse sowie weitere Dialysetherapien und -dienstleistungen; intravenöse Therapien, Infusionspumpen, Verabreichungssets und Geräte zur Medikamentenrekonstitution; neu gemischte und onkologische Arzneimittelplattformen, Inhalationsanästhesie- und Intensivpflegeprodukte sowie Apothekenmischungen; parenterale Ernährungstherapien und zugehörige Produkte; biologische Produkte und medizinische Geräte, die bei chirurgischen Eingriffen zur Blutstillung, Gewebeversiegelung und Verhinderung von Adhäsionen verwendet werden; sowie kontinuierliche Nierenersatztherapien und andere Therapien zur Organunterstützung mit Schwerpunkt auf der Intensivstation. Darüber hinaus bietet das Unternehmen vernetzte Pflegelösungen an, darunter Geräte, Software, Kommunikations- und Integrationstechnologien; integrierte Patientenüberwachungs- und Diagnosetechnologien, die bei der Diagnose, Behandlung und dem Management verschiedener Krankheiten und Leiden helfen, darunter Atemtherapie, Kardiologie, Sehtests und physische Beurteilung; chirurgische Videotechnologien, Tische, Leuchten, Anhänger, Präzisionspositionierungsgeräte und anderes Zubehör. Darüber hinaus bietet das Unternehmen verschiedenen pharmazeutischen und biopharmazeutischen Unternehmen vertragliche Dienstleistungen an. Seine Produkte werden in Krankenhäusern, Nierendialysezentren, Pflegeheimen, Rehabilitationszentren, Arztpraxen und bei Patienten zu Hause unter ärztlicher Aufsicht eingesetzt. Das Unternehmen vertreibt seine Produkte über den Direktvertrieb sowie über unabhängige Distributoren, Arzneimittelgroßhändler und Spezialapotheken oder andere Anbieter alternativer Standorte in rund 100 Ländern. Es hat eine Vereinbarung mit Celerity Pharmaceutical, LLC zur Entwicklung von injizierbaren Vormischungen für die Akutversorgung und onkolytischen Molekülen. Baxter International Inc. wurde 1931 gegründet und hat seinen Hauptsitz in Deerfield, Illinois.

Name
Baxter International
CEO
David Brent Shafer
SitzDeerfield, il
USA
Website
Industrie
Gesundheitstechnologie
Börsengang
Mitarbeiter38.000

Ticker Symbole

BörseSymbol
NYSE
BAX
London Stock Exchange
0QK8.L
SIX
BAX.SW
Frankfurt
BTL.F
Düsseldorf
BTL.DU
Hamburg
BTL.HM
Milan
1BAX.MI
London
0QK8.L
München
BTL.MU
Wien
BAX.VI

Assets entdecken

Shareholder von Baxter International investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr